{"nctId":"NCT00769860","briefTitle":"Arimoclomol in Sporadic Inclusion Body Myositis","startDateStruct":{"date":"2008-09"},"conditions":["Inclusion Body Myositis"],"count":24,"armGroups":[{"label":"1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Arimoclomol"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Arimoclomol","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Meet the diagnostic criteria for definite or probable IBM (Griggs 1995)\n* Muscle function adequate for quantitative muscle testing\n* Age \\> 50 years\n* Women must be postmenopausal or status post hysterectomy\n* For any patient currently taking medication for IBM, they must remain on current dosage for the extent of the study and last dosage change must be \\> 30 days previous to enrollment\n\nExclusion Criteria:\n\n* Presence of any one of the following medical conditions: diabetes mellitus or patients taking anti-diabetic medications, chronic infection, chronic renal insufficiency, cancer other than skin cancer less than 5 years previously, multiple sclerosis or prior episode or central nervous system demyelination, or other chronic serious medical illnesses\n* Presence of any of the following on routine blood screening: WBC \\< 3000, platelets \\< 100,000, hematocrit \\< 30%, BUN \\> 30 mg%, creatine \\> 1.5 mg%, symptomatic liver disease with serum albumin \\< 3 g/dl, PT or PTT \\> upper range of control values\n* Women who are pregnant or lactating\n* History of non-compliance with other therapies\n* Coexistence of other neuromuscular disease\n* Drug or alcohol abuse within the last 3 months\n* Inability to give informed consent\n* Known bleeding disorder\n* Use of potentially renal toxic drugs\n* Prior difficulties with local anesthetic","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Count of Adverse Events Reported","description":"Measure reflects the total number of adverse events reported during course of the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]}]},{"type":"SECONDARY","title":"Heat Shock Protein 70 (HSP70) Levels in the Tissue","description":"Biopsy taken from participants at baseline and month 4 visits. Measured change in HSP70 levels in the tissue.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-110.72","spread":"757.40"},{"groupId":"OG001","value":"-34.70","spread":"336.35"}]}]}]},{"type":"SECONDARY","title":"Muscle Strength Testing","description":"Change in MMT score for the period. The MMT score range is 0-5. A score of 0 is the lowest and represents no visible or palpable contraction. A score of 5 is the highest and represents full range of motion against gravity, maximal resistance.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":"0.19"},{"groupId":"OG001","value":"-0.12","spread":"0.20"}]}]}]},{"type":"SECONDARY","title":"Muscle Strength Testing","description":"Change in MMT score for the period. The MMT score range is 0-5. A score of 0 is the lowest and represents no visible or palpable contraction. A score of 5 is the highest and represents full range of motion against gravity, maximal resistance.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.12","spread":"0.22"},{"groupId":"OG001","value":"-0.26","spread":"0.27"}]}]}]},{"type":"SECONDARY","title":"Muscle Strength Testing","description":"Change in MMT score for the period. The MMT score range is 0-5. A score of 0 is the lowest and represents no visible or palpable contraction. A score of 5 is the highest and represents full range of motion against gravity, maximal resistance.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.21","spread":"0.21"},{"groupId":"OG001","value":"-0.35","spread":"0.20"}]}]}]},{"type":"SECONDARY","title":"Inclusion Body Myositis-Functional Rating Scale (IBMFRS) Score","description":"Measured change for the period. The questionnaire has 10 questions. The maximum score is 40. The higher the score the better the functional status of the patient.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.34","spread":"1.38"},{"groupId":"OG001","value":"-0.88","spread":"1.16"}]}]}]},{"type":"SECONDARY","title":"Inclusion Body Myositis-Functional Rating Scale (IBMFRS) Score","description":"Measured change for the period. The questionnaire has 10 questions. The maximum score is 40. The higher the score the better the functional status of the patient.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.68","spread":"1.58"},{"groupId":"OG001","value":"-2.50","spread":"3.31"}]}]}]},{"type":"SECONDARY","title":"Inclusion Body Myositis-Functional Rating Scale (IBMFRS) Score","description":"Measured change for the period. The questionnaire has 10 questions. The maximum score is 40. The higher the score the better the functional status of the patient.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.03","spread":"2.68"},{"groupId":"OG001","value":"-3.50","spread":"3.35"}]}]}]},{"type":"SECONDARY","title":"Maximum Isometric Voluntary Contraction Testing (MVICT) Score","description":"Measured MVICT using the Quantitative Muscle Assessment (QMA) system designed by Computer Source, Atlanta, GA. The system uses an adjustable cuff to attach the patient's arm or leg to an inelastic strap that is connected to force transducer with a load of 0.5 to 1,000 Newtons. Maximum force is recorded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.46","spread":"12.11"},{"groupId":"OG001","value":"-0.30","spread":"14.49"}]}]}]},{"type":"SECONDARY","title":"Maximum Isometric Voluntary Contraction Testing (MVICT) Score","description":"Measured MVICT using the Quantitative Muscle Assessment (QMA) system designed by Computer Source, Atlanta, GA. The system uses an adjustable cuff to attach the patient's arm or leg to an inelastic strap that is connected to force transducer with a load of 0.5 to 1,000 Newtons. Maximum force is recorded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.20","spread":"19.65"},{"groupId":"OG001","value":"-1.71","spread":"17.80"}]}]}]},{"type":"SECONDARY","title":"Maximum Isometric Voluntary Contraction Testing (MVICT) Score","description":"Measured MVICT using the Quantitative Muscle Assessment (QMA) system designed by Computer Source, Atlanta, GA. The system uses an adjustable cuff to attach the patient's arm or leg to an inelastic strap that is connected to force transducer with a load of 0.5 to 1,000 Newtons. Maximum force is recorded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.21","spread":"20.76"},{"groupId":"OG001","value":"0.52","spread":"17.98"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":16},"commonTop":["Fall/contusion","Constipation","Upper respiratory tract infection","Musculoskeletal pain","Loose stools"]}}}